260 million! The cooperation between two well-known pharmaceutical companies was terminated.

On September 9th, Haisco Pharmaceutical Group Co., Ltd. announced that its wholly-owned subsidiary, Sichuan Haisco Pharmaceutical Co., Ltd., had signed the Patent Implementation License Agreement and related agreement with Chengdu Haitron Pharmaceutical Co., Ltd. ("Haitron Pharmaceuticals") on September 4th, 2020 .
After friendly consultations between the two sides, Sichuan Haisco will grant exclusive license to HC-1119 and the patented products and patented methods of various pharmaceutical preparations with which it is an active ingredient (collectively, "HC-1119 Patented Products"), as a result of the new The technical achievements and their co-ownership of supporting property rights and their transfer of all rights to clinical trials, drug registration certificates and new drug certificates, research and development rights, production rights, sales rights, commercialization rights, trademarks (generic names) and other intellectual property rights to Haitron Pharmaceuticals, with a total transfer value of RMB260 million, to be paid in three phases.
According to the signed transaction agreement, the Company expects to receive a total of RMB110 million in the first and second inse terms in 2020, and according to preliminary estimates, the Company is expected to receive a total of approximately RMB17.46 million in revenue, or RMB150 million in revenue, which will need to be confirmed in the future in the third period agreed upon in the agreement, when the terms of payment are reached.
do you want and what's the future? The partnership dates back four years, and on October 24, 2016, Sichuan Haicheng Pharmaceutical Co., Ltd. signed a capital increase agreement and a patent implementation license agreement in Chengdu.
the relevant agreement, Sichuan Haisco intends to use the company's own funds of RMB33.454 million to invest equity in the enterprise.
Under the Patent Implementation License Agreement, Sichuan Haisco will obtain exclusive license for prostate tumor drugs developed by Haitron Pharmaceuticals' patented technology, namely HC-1119 and various pharmaceutical preparations with which they are active ingredients, in China.
It is understood that HC-1119 series of haitron pharmaceutical industry independently developed prostate cancer drugs, belonging to androgen-like antagonists, can be in the target tissue with androgen-like, blocking the binding of testosterone and androgen-liker, inhibiting the target tissue intake of testosterone, thus playing an anti-androgen and inhibit the growth of prostate cancer cells.
2019, the company has seven innovative pharmaceutical products, including prostate cancer drugs (HC-1119) China Phase III clinical trials continue to advance, is expected to be declared in 2020 production.
the termination of the cooperation, Hesco for 260 million yuan to the drug's exclusive licensing rights and other subsequent transfer of all subsequent rights to Haitron Pharmaceuticals, how much impact will it have? Prostate cancer is the second most common type of cancer among men worldwide, with about one in nine men diagnosed with prostate cancer in their lifetimes and about 1.3 million newly diagnosed cases worldwide in 2018, according to public data.
174.65 million cases are expected to be diagnosed with prostate cancer in the United States in 2019.
, prostate cancer is the most common genitourinary cancer in men, with a incidence rate of about 98 per 100,000 people.
HC-1119 is a representative first-line treatment for metastasis CRPC, which will be available domestically in 2019 and has global sales of $3.624 billion in 2018, according to Drug Crossing.
Previously, in addition to ensergies, Johnson and Johnson's acetic acid abitron, a best-selling drug in prostate therapy, has dominated the market since its launch in 2011, with global sales of $2.51 billion in 2017 and a peak of $3.5 billion in sales in 2018, thanks to an explosion in Europe.
it is worth noting, however, that Abitron was included in the second batch of national collections in January 2020, and that the price of Abitorn tablets (trademark name: clear coshu) has fallen by 77%.
it remains to be known how much market the HC-1119 will gain when it companies go public in the future, following the strong grip of Abitron and Enrugluamine.
rich research and development pipeline Haisco Pharmaceutical Group Co., Ltd. is a new drug research and development, manufacturing, sales and other business in one of the diversified, specialized pharmaceutical group listed companies.
's 2019 annual report shows that during the reporting period, the company achieved operating income of RMB3.93 billion, up 14.90% YoY, and net profit of RMB490 million, up 48.21% YoY.
company's existing main products for the vast majority of the first or exclusive imitation, the existing sales varieties of 36.
products sold in the domestic market, mainly including polyole phosphatidylcholine injection, injection of fat-soluble vitamin series, methulphate dorasjun injection, hydrochloric acid naloxone injection, fluorophenidumab, injection of cephalosporine sodium tazepam sodium, involving liver disease, extraintestinal nutrition, depression, antibiotics and other fields.
from the progress of Hesco's innovative drug research and development, by the end of 2019, the company has seven innovative pharmaceutical products, mainly: HSK-3486 in anesthesia sedation has submitted a listing application, is expected to be approved in 2020; Phase II. Phase II clinical, long-acting diabetes HSK-7653 has begun clinical phase II.Phase II.Phase II. Phase I., HSK-16149 in diabetic terminal nerve pain, HSK-21542 for exogerytic analgesics, and FTP-198 for pulmonary fibrosis have begun Clinical Phase I.
company in the development of 68 drugs, including 55 generic drugs, 7 innovative drugs, special medical use formula food 5, medical equipment 1;
reporting period, 2 new clinical declaration items, 7 new listed declaration items (including 1 RAW drug, 6 preparations), 7 new consistent evaluation and declaration items.
said the company continued to maintain a high investment in research and development of 526 million yuan, accounting for 13.35 percent of operating income, of which the capitalization amount of 314 million yuan, accounting for 59.72 percent of research and development investment.
the company will continue to increase investment in research and development projects, especially in innovative drug research and development investment will be very large.
To some extent, Hesco's research and development pipeline is perfect, still maintain high research and development investment, so the impact of the termination of a drug cooperation will continue to weaken, how to adjust its pipeline in the future, how to adjust the future research and development strategy, Seber blue will continue to maintain attention.
.